Prognostic value of the systemic immune-inflammation index in non-muscle invasive bladder cancer
Standard
Prognostic value of the systemic immune-inflammation index in non-muscle invasive bladder cancer. / Katayama, Satoshi; Mori, Keiichiro; Pradere, Benjamin; Laukhtina, Ekaterina; Schuettfort, Victor M; Quhal, Fahad; Motlagh, Reza Sari; Mostafaei, Hadi; Grossmann, Nico C; Rajwa, Pawel; Moschini, Marco; Mathieu, Romain; Abufaraj, Mohammad; D'Andrea, David; Compérat, Eva; Haydter, Martin; Egawa, Shin; Nasu, Yasutomo; Shariat, Shahrokh F; European Association of Urology – Young Academic Urologists (EAU-YAU), Urothelial Carcinoma Working Group.
in: WORLD J UROL, Jahrgang 39, Nr. 12, 12.2021, S. 4355-4361.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Prognostic value of the systemic immune-inflammation index in non-muscle invasive bladder cancer
AU - Katayama, Satoshi
AU - Mori, Keiichiro
AU - Pradere, Benjamin
AU - Laukhtina, Ekaterina
AU - Schuettfort, Victor M
AU - Quhal, Fahad
AU - Motlagh, Reza Sari
AU - Mostafaei, Hadi
AU - Grossmann, Nico C
AU - Rajwa, Pawel
AU - Moschini, Marco
AU - Mathieu, Romain
AU - Abufaraj, Mohammad
AU - D'Andrea, David
AU - Compérat, Eva
AU - Haydter, Martin
AU - Egawa, Shin
AU - Nasu, Yasutomo
AU - Shariat, Shahrokh F
AU - European Association of Urology – Young Academic Urologists (EAU-YAU), Urothelial Carcinoma Working Group
N1 - © 2021. The Author(s).
PY - 2021/12
Y1 - 2021/12
N2 - PURPOSE: We assessed the prognostic value of systemic immune-inflammation index (SII) to refine risk stratification of the heterogeneous spectrum of patients with non-muscle-invasive bladder cancer (NMIBC) METHODS: In this multi-institutional cohort, preoperative blood-based SII was retrospectively assessed in 1117 patients with NMIBC who underwent transurethral resection of bladder (TURB) between 1996 and 2007. The optimal cut-off value of SII was determined as 580 using the best Youden index. Cox regression analyses were performed. The concordance index (C-index) and decision curve analysis (DCA) were used to assess the discrimination of the predictive models.RESULTS: Overall, 309 (28%) patients had high SII. On multivariable analyses, high SII was significantly associated with worse PFS (hazard ratio [HR] 1.84; 95% confidence interval [CI] 1.23-2.77; P = 0.003) and CSS (HR 2.53; 95% CI 1.42-4.48; P = 0.001). Subgroup analyses, according to the European Association of Urology guidelines, demonstrated the main prognostic impact of high SII, with regards to PFS (HR 3.39; 95%CI 1.57-7.31; P = 0.002) and CSS (HR 4.93; 95% CI 1.70-14.3; P = 0.005), in patients with intermediate-risk group; addition of SII to the standard predictive model improved its discrimination ability both on C-index (6% and 12%, respectively) and DCA. In exploratory intergroup analyses of patients with intermediate-risk, the improved discrimination ability was retained the prediction of PFS and CSS.CONCLUSION: Preoperative SII seems to identify NMIBC patients who have a worse disease and prognosis. Such easily available and cheap standard biomarkers may help refine the decision-making process regarding adjuvant treatment in patients with intermediate-risk NMIBC.
AB - PURPOSE: We assessed the prognostic value of systemic immune-inflammation index (SII) to refine risk stratification of the heterogeneous spectrum of patients with non-muscle-invasive bladder cancer (NMIBC) METHODS: In this multi-institutional cohort, preoperative blood-based SII was retrospectively assessed in 1117 patients with NMIBC who underwent transurethral resection of bladder (TURB) between 1996 and 2007. The optimal cut-off value of SII was determined as 580 using the best Youden index. Cox regression analyses were performed. The concordance index (C-index) and decision curve analysis (DCA) were used to assess the discrimination of the predictive models.RESULTS: Overall, 309 (28%) patients had high SII. On multivariable analyses, high SII was significantly associated with worse PFS (hazard ratio [HR] 1.84; 95% confidence interval [CI] 1.23-2.77; P = 0.003) and CSS (HR 2.53; 95% CI 1.42-4.48; P = 0.001). Subgroup analyses, according to the European Association of Urology guidelines, demonstrated the main prognostic impact of high SII, with regards to PFS (HR 3.39; 95%CI 1.57-7.31; P = 0.002) and CSS (HR 4.93; 95% CI 1.70-14.3; P = 0.005), in patients with intermediate-risk group; addition of SII to the standard predictive model improved its discrimination ability both on C-index (6% and 12%, respectively) and DCA. In exploratory intergroup analyses of patients with intermediate-risk, the improved discrimination ability was retained the prediction of PFS and CSS.CONCLUSION: Preoperative SII seems to identify NMIBC patients who have a worse disease and prognosis. Such easily available and cheap standard biomarkers may help refine the decision-making process regarding adjuvant treatment in patients with intermediate-risk NMIBC.
U2 - 10.1007/s00345-021-03740-3
DO - 10.1007/s00345-021-03740-3
M3 - SCORING: Journal article
C2 - 34143284
VL - 39
SP - 4355
EP - 4361
JO - WORLD J UROL
JF - WORLD J UROL
SN - 0724-4983
IS - 12
ER -